Risk Factors of Jabbour et al for Outcome in a Patient with Ph+ Chronic Myeloid Leukemia (CML) in Chronic Phase Treated with Nilotinib After Imatinib

 

Patient selection: Ph+ CML, resistant to or intolerant of imatinib, treated with nilotinib

 

Outcomes: progression-free survival, overall survival

 

Factors associated with worse outcomes (3 known at baseline, 1 known within 12 months):

(1) baseline hemoglobin < 12 g/dL

(2) baseline percent basophils >= 4%

(3) baseline mutation with low sensitivity to nilotinib

(4) absence of major cytogenetic respsonse within 12 months (drug resistance)

 

Outcomes were best when all 4 factors were absent and worst when all 4 were present.